


Invitation

Precision therapy in NSCLC: the dawn of KRAS^{G12C} inhibition

Saturday 18 September 2021 / 10.30–12.00 CEST / Channel 4



Faculty:



Michael Thomas



Ernest Nadal



Aleš Ryška

Programme:

- **Welcome and Introduction**
Michael Thomas, Heidelberg University Hospital, Germany
- **Targeting the undruggable: what we know about KRAS-mutant NSCLC**
Ernest Nadal, Catalan Institute of Oncology, Spain
- **Harnessing the power of biomarkers to treat NSCLC**
Aleš Ryška, Charles University, Czech Republic
- **Expanding treatment options for patients with KRAS G12C-mutant NSCLC**
Michael Thomas, Heidelberg University Hospital, Germany
- **Panel discussion**
All

AMGEN
Oncology